JP2023550079A5 - - Google Patents
Info
- Publication number
- JP2023550079A5 JP2023550079A5 JP2023529034A JP2023529034A JP2023550079A5 JP 2023550079 A5 JP2023550079 A5 JP 2023550079A5 JP 2023529034 A JP2023529034 A JP 2023529034A JP 2023529034 A JP2023529034 A JP 2023529034A JP 2023550079 A5 JP2023550079 A5 JP 2023550079A5
- Authority
- JP
- Japan
- Prior art keywords
- rilpivirine
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- hyaluronidase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063114997P | 2020-11-17 | 2020-11-17 | |
| US63/114,997 | 2020-11-17 | ||
| PCT/US2021/072453 WO2022109555A1 (en) | 2020-11-17 | 2021-11-17 | Treatment or prevention of hiv infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023550079A JP2023550079A (ja) | 2023-11-30 |
| JP2023550079A5 true JP2023550079A5 (enExample) | 2024-11-26 |
Family
ID=86558047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023529034A Pending JP2023550079A (ja) | 2020-11-17 | 2021-11-17 | Ｈｉｖ感染症の治療又は予防 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230405001A1 (enExample) |
| EP (1) | EP4247342A1 (enExample) |
| JP (1) | JP2023550079A (enExample) |
| KR (1) | KR20230110548A (enExample) |
| CN (1) | CN116437923A (enExample) |
| AU (1) | AU2021383922A1 (enExample) |
| CA (1) | CA3196799A1 (enExample) |
| IL (1) | IL302856A (enExample) |
| JO (1) | JOP20230108A1 (enExample) |
| MX (1) | MX2023005758A (enExample) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ542873A (en) * | 2003-03-05 | 2008-07-31 | Halozyme Inc | Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA |
-
2021
- 2021-11-17 MX MX2023005758A patent/MX2023005758A/es unknown
- 2021-11-17 CN CN202180077125.2A patent/CN116437923A/zh active Pending
- 2021-11-17 EP EP21824738.5A patent/EP4247342A1/en active Pending
- 2021-11-17 JP JP2023529034A patent/JP2023550079A/ja active Pending
- 2021-11-17 KR KR1020237020228A patent/KR20230110548A/ko active Pending
- 2021-11-17 US US18/037,204 patent/US20230405001A1/en active Pending
- 2021-11-17 IL IL302856A patent/IL302856A/en unknown
- 2021-11-17 AU AU2021383922A patent/AU2021383922A1/en active Pending
- 2021-11-17 CA CA3196799A patent/CA3196799A1/en active Pending
-
2023
- 2023-05-16 JO JOJO/P/2023/0108A patent/JOP20230108A1/ar unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018162283A5 (ja) | 組成物、医薬組成物、医薬製剤、及びそれらの形成方法 | |
| JP4123309B2 (ja) | 鼻内投与のための薬学的非無機塩類液剤 | |
| JP2017533201A5 (enExample) | ||
| JP2023535744A5 (enExample) | ||
| JP2013532729A5 (enExample) | ||
| CN106109455A (zh) | 以5‑氨基乙酰丙酸或其衍生物作为有效成分的抗疟药 | |
| JP2022502432A5 (enExample) | ||
| CN103298464A (zh) | 复方组合物 | |
| HUE026994T2 (en) | Liquid nasal spray containing low dose naltrexone | |
| JP2022518944A5 (enExample) | ||
| JP2022539077A5 (enExample) | ||
| CN104918619A (zh) | 稳定的肠胃外dnj组合物 | |
| CN103370066A (zh) | 用于治疗癌症的包含威罗菲尼和干扰素的组合疗法 | |
| JP2025517509A5 (enExample) | ||
| JP2023550079A5 (enExample) | ||
| CN109996554A (zh) | 新型抗微生物和抗癌疗法 | |
| CN102740845A (zh) | 微生物感染的治疗 | |
| JP2023549837A5 (enExample) | ||
| US11497747B2 (en) | Compositions and methods for treating lung injuries associated with SARS-CoV-2 infections | |
| JP2012502983A (ja) | 新規単回単位カルバペネムアミノグリコシド製剤 | |
| JP2024515555A5 (enExample) | ||
| CN101505765A (zh) | 用于注射给药、特别是靶向局部给药的药物组合物 | |
| CN115843267A (zh) | 呼吸道病毒感染的治疗 | |
| CN111374981A (zh) | 匹莫齐特和甲氨蝶呤的药物组合及其应用 | |
| WO2020051473A1 (en) | Infection-induced endothelial amyloid compositions as antimicrobials |